How much profit has Regenxbio made this year?
Regenxbio has made -238.61 M USD this year.
Regenxbio Net Income 2024
Regenxbio Net Income
-238.61 M USD
Ticker
RGNX
ISIN
US75901B1070
WKN
A140E0
In 2024, Regenxbio's profit amounted to -238.61 M USD, a -9.44% increase from the -263.49 M USD profit recorded in the previous year.
The Regenxbio Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 214.8 |
| 2028e | 44.48 |
| 2027e | -55.85 |
| 2026e | -183.97 |
| 2025e | -53.89 |
| 2024e | -238.61 |
| 2023 | -263.49 |
| 2022 | -280.3 |
| 2021 | 127.8 |
| 2020 | -111.3 |
| 2019 | -94.7 |
| 2018 | 99.9 |
| 2017 | -73.2 |
| 2016 | -63 |
| 2015 | -23.8 |
| 2014 | -4.8 |
| 2013 | -5.8 |
Regenxbio Revenue, EBIT, Net Income US75901B1070 · A140E0
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Regenxbio, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Regenxbio from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Regenxbio’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Regenxbio. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Regenxbio’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Regenxbio’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Regenxbio’s growth potential.
Regenxbio Revenue, EBIT and net profit per share
| Date | Regenxbio Revenue | Regenxbio EBIT | Regenxbio Net Income |
|---|---|---|---|
| 2029e | 893.4 M undefined | 0 undefined | 214.8 M undefined |
| 2028e | 592.24 M undefined | -80.2 M undefined | 44.48 M undefined |
| 2027e | 451.94 M undefined | -110 M undefined | -55.85 M undefined |
| 2026e | 261.89 M undefined | -79.51 M undefined | -183.97 M undefined |
| 2025e | 306.51 M undefined | -91.91 M undefined | -53.89 M undefined |
| 2024e | 97.38 M undefined | -232.27 M undefined | -238.61 M undefined |
| 2023 | 90.24 M undefined | -268.13 M undefined | -263.49 M undefined |
| 2022 | 112.7 M undefined | -262.9 M undefined | -280.3 M undefined |
| 2021 | 470.3 M undefined | 160 M undefined | 127.8 M undefined |
| 2020 | 154.6 M undefined | -119.2 M undefined | -111.3 M undefined |
| 2019 | 35.2 M undefined | -149 M undefined | -94.7 M undefined |
| 2018 | 218.5 M undefined | 88.1 M undefined | 99.9 M undefined |
| 2017 | 10.4 M undefined | -75.9 M undefined | -73.2 M undefined |
| 2016 | 4.6 M undefined | -65.3 M undefined | -63 M undefined |
| 2015 | 7.6 M undefined | -23.1 M undefined | -23.8 M undefined |
| 2014 | 6.1 M undefined | -3.7 M undefined | -4.8 M undefined |
| 2013 | 6.1 M undefined | -4.8 M undefined | -5.8 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 6.1 M USD | -4.8 M USD | -5.8 M USD |
| 2014 | 6.1 M USD | -3.7 M USD | -4.8 M USD |
| 2015 | 7.6 M USD | -23.1 M USD | -23.8 M USD |
| 2016 | 4.6 M USD | -65.3 M USD | -63 M USD |
| 2017 | 10.4 M USD | -75.9 M USD | -73.2 M USD |
| 2018 | 218.5 M USD | 88.1 M USD | 99.9 M USD |
| 2019 | 35.2 M USD | -149 M USD | -94.7 M USD |
| 2020 | 154.6 M USD | -119.2 M USD | -111.3 M USD |
| 2021 | 470.3 M USD | 160 M USD | 127.8 M USD |
| 2022 | 112.7 M USD | -262.9 M USD | -280.3 M USD |
| 2023 | 90.24 M USD | -268.13 M USD | -263.49 M USD |
| 2024e | 97.38 M USD | -232.27 M USD | -238.61 M USD |
| 2025e | 306.51 M USD | -91.91 M USD | -53.89 M USD |
| 2026e | 261.89 M USD | -79.51 M USD | -183.97 M USD |
| 2027e | 451.94 M USD | -110 M USD | -55.85 M USD |
| 2028e | 592.24 M USD | -80.2 M USD | 44.48 M USD |
| 2029e | 893.4 M USD | 0 USD | 214.8 M USD |
Regenxbio stock margins US75901B1070 · A140E0
The Regenxbio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Regenxbio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Regenxbio.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Regenxbio's sales revenue. A higher gross margin percentage indicates that the Regenxbio retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Regenxbio's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Regenxbio's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Regenxbio's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Regenxbio. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Regenxbio's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Regenxbio Margin History
| Regenxbio Gross margin | Regenxbio Profit margin | Regenxbio EBIT margin | Regenxbio Profit margin |
|---|---|---|---|
| 2029e | 58.76 % | 0 % | 24.04 % |
| 2028e | 58.76 % | -13.54 % | 7.51 % |
| 2027e | 58.76 % | -24.34 % | -12.36 % |
| 2026e | 58.76 % | -30.36 % | -70.25 % |
| 2025e | 58.76 % | -29.99 % | -17.58 % |
| 2024e | 58.76 % | -238.51 % | -245.03 % |
| 2023 | 58.76 % | -297.12 % | -291.99 % |
| 2022 | 51.64 % | -233.27 % | -248.71 % |
| 2021 | 88.99 % | 34.02 % | 27.17 % |
| 2020 | 76.91 % | -77.1 % | -71.99 % |
| 2019 | 76.7 % | -423.3 % | -269.03 % |
| 2018 | 95.61 % | 40.32 % | 45.72 % |
| 2017 | 83.65 % | -729.81 % | -703.85 % |
| 2016 | 78.26 % | -1,419.57 % | -1,369.57 % |
| 2015 | 80.26 % | -303.95 % | -313.16 % |
| 2014 | 83.61 % | -60.66 % | -78.69 % |
| 2013 | 95.08 % | -78.69 % | -95.08 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 95.08 % | -78.69 % | -95.08 % |
| 2014 | 83.61 % | -60.66 % | -78.69 % |
| 2015 | 80.26 % | -303.95 % | -313.16 % |
| 2016 | 78.26 % | -1,419.57 % | -1,369.57 % |
| 2017 | 83.65 % | -729.81 % | -703.85 % |
| 2018 | 95.61 % | 40.32 % | 45.72 % |
| 2019 | 76.7 % | -423.3 % | -269.03 % |
| 2020 | 76.91 % | -77.1 % | -71.99 % |
| 2021 | 88.99 % | 34.02 % | 27.17 % |
| 2022 | 51.64 % | -233.27 % | -248.71 % |
| 2023 | 58.76 % | -297.12 % | -291.99 % |
| 2024e | 58.76 % | -238.51 % | -245.03 % |
| 2025e | 58.76 % | -29.99 % | -17.58 % |
| 2026e | 58.76 % | -30.36 % | -70.25 % |
| 2027e | 58.76 % | -24.34 % | -12.36 % |
| 2028e | 58.76 % | -13.54 % | 7.51 % |
| 2029e | 58.76 % | 0 % | 24.04 % |
Regenxbio Aktienanalyse
What does Regenxbio do?
Regenxbio Inc is a biopharmaceutical company that specializes in the development of AAV-based gene therapies for rare genetic diseases. The company was founded in 2009 in Maryland, USA and has since developed an impressive portfolio of therapy options. The history of Regenxbio Inc begins with the realization that gene therapies offer a promising way to treat rare genetic diseases for which there are currently no cures. However, at that time, there were still many technical and regulatory hurdles to overcome. Regenxbio took on these challenges and specialized in the development of adeno-associated viruses (AAV) as vectors for the transfer of therapeutic genes, as these viruses are ideally suited for this purpose. The business model of Regenxbio Inc is based on licensing its technology platform to other companies, which can then develop their own gene therapies. The company has already formed partnerships with major pharmaceutical companies such as AstraZeneca and Novartis, who utilize Regenxbio's technology platform to develop new therapy options for rare diseases. A significant aspect of Regenxbio Inc is the discovery and development of gene therapies for rare diseases. These include diseases such as choroideremia syndrome and mucopolysaccharidosis type I, among others. The company has already conducted clinical trials that have shown promising results and has received approval in the EU. Regenxbio aims to replace invasive and complicated treatments with gene therapy options. Additionally, Regenxbio Inc also offers services in the manufacturing of AAV-based gene therapies. The company supports other firms in the production and quality control of AAV vectors required for the manufacturing of gene therapies. This business sector plays a crucial role in the distribution of therapies to the market. The ultimate goal of Regenxbio Inc is to improve the quality of life for individuals suffering from rare genetic diseases through the development and commercialization of gene therapies. With innovative technologies and partnerships with other pharmaceutical companies, the company has already established an important role in the field of gene therapy development. Overall, the company has a very positive future outlook and will remain under observation in the healthcare industry. Regenxbio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Regenxbio's Profit Margins
The profit margins of Regenxbio represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Regenxbio's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Regenxbio's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Regenxbio's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Regenxbio’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Regenxbio stock
How has the profit developed compared to last year?
The profit has increased by -9.44% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Regenxbio publish its earnings?
Regenxbio publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Regenxbio?
The profits of Regenxbio are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Regenxbio?
You can learn more about the earnings of Regenxbio by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Regenxbio pay?
Over the past 12 months, Regenxbio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regenxbio is expected to pay a dividend of 0 USD.
What is the dividend yield of Regenxbio?
The current dividend yield of Regenxbio is .
When does Regenxbio pay dividends?
Regenxbio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Regenxbio?
Regenxbio paid dividends every year for the past 0 years.
What is the dividend of Regenxbio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Regenxbio located?
Regenxbio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Regenxbio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Regenxbio from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.
When did Regenxbio pay the last dividend?
The last dividend was paid out on 11/20/2024.
What was the dividend of Regenxbio in the year 2023?
In the year 2023, Regenxbio distributed 0 USD as dividends.
In which currency does Regenxbio pay out the dividend?
The dividends of Regenxbio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Regenxbio
Our stock analysis for Regenxbio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regenxbio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
